|CGT9486 (Bezuclastinib)+Sunitinib vs. Sunitinib alone in advanced GIST
|CGT9486 (Bezuclastinib), Sunitinib
|Cogent Biosciences, Inc.
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib in locally advanced, metastatic, and/or unresectable GIST.
Further information can be found on clinicaltrials.gov.
WHO is the trial for?
WHAT is the key question that this trial is attempting to answer?
|The study wants to assess whether the combination of CGT9486 (Bezuclastinib)+Sunitinib is superior in efficacy compared to Sunitinib alone.
Bezuclastinib is a tyrosine kinase inhibitor that selectively targets a specific range of KIT mutations. This includes some mutations that sunitinib does not work against. The key question this trial aims to answers is if the combination of bezuclastinib and sunitinib have the potential to provide complementary coverage across a number of mutations in the KIT gene.
WHY patients might want to participate?
|This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in GIST and potentially help other patients with this disease.
The trial might or might not have benefit in your individual case.
WHEN will the trial be open?
|The study is open for recruitment.
WHERE is the trial available?
|The trial is currently active in the US, Australia, Canada, Denmark, France, Germany, the Republic of Korea, Netherlands, Sweden and Taiwan.
Please check for current information here.
STUDY DESIGN: What does the study look like?
|The trial will be conducted in two parts:
HOW do I get more information?
|Patient organizations supporting GIST and/or sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving GIST and/or sarcoma patients. If there are no such organization in your country, please email us for more information: firstname.lastname@example.org
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.